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other than those reported in literature about SBRT and SBRS 
on abdominal area. 
 
EP-1207  
Can DIBH technique be used for SABR of large and mobile 
tumors of lung and liver? A clinical study 
C. Srinivas
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1, S. Subramaniam1, N. Mohammed1, A. Gandhi1, M. 
Kathirvel1, T. Swamy1, K. Kiran Kumar1, A. Jotwani1, N. 
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Purpose or Objective: To assess clinical feasibility, local 
control and toxicity of deep inspiratory breath hold (DIBH) 
technique for delivery of SABR for large and mobile tumors of 
lung and liver. 
 
Material and Methods: All patients suitable to undergo SABR, 
underwent respiratory training consisting of DIBH on demand 
for 15-25 seconds at a time. Patients underwent 2 sets of 
immobilization and imaging, one in DIBH phase and other in 
free breathing (FB) phase. Respiratory monitoring was 
performed using Varian RPM system and a 4mm gating 
threshold window was allowed. Set-up verification was 
performed using KV imaging and gated cone beam CT both 
taken in DIBH. All patients were planned with 2-4 arc VMAT 
using 6MV flattening filter free (FFF) photon beams to a dose 
of 60Gy in 5 fractions. 
 
Results: 12 patients of lung tumors and 9 patients of liver 
tumors were treated with DIBH based SABR. In patients with 
lung tumors, DIBH resulted in 1.53 times higher mean lung 
volumes (3937 cc vs. 2576 cc, p=0.003). Compared to ITV 
based contours, PTV volumes were 1.48 times smaller for 
lung and 1.38 times smaller for liver tumors in DIBH CT 
compared to FB CT (36.15 cc vs. 53.83 cc, p=0.002, 57.76cc 
vs. 79.78, p=0.03). All the plans accepted for delivery met 
the standard criteria (ROSEL for lung and RTOG 1112 for 
liver) for both target and OAR constraints. On an average, 
V20 was reduced by 30%(18-38) in DIBH plans compared to FB 
plans. Time taken to deliver each session in DIBH phase with 
FFF beams was longer by an average of 2 minutes due to 
interruptions (maximum 4 interruptions/arc each lasting <10 
seconds). Mean setup errors in cm quantified on CBCT were 
0.1, 0.2 and 0.1 in vertical, longitudinal and lateral 
dimensions respectively and a uniform margin (based on Van 
Herk's formula) of 4mm appears to be safe. Except for 1 
patient with symptomatic grade 2 pneumonitis and 1 patient 
with grade 2 chest wall pain, none had any major toxicities. 
With a median follow-up of 16 months, 18 month local 
control was 95%.  
 
Conclusion: DIBH based SABR is clinically feasible and 
effective and should be considered standard for treating 
mobile and especially large tumors of lung and liver provided 
patient is suitable for treatment with DIBH technique. DIBH-
CBCT based verification appears to be reproducible and 
effective to reduce setup errors. A margin of 4 mm appears 
to be safe in DIBH setting with 4 mm gating threshold 
window. Despite minimal increase in treatment time, DIBH is 
an effective way to deliver high throughput high quality 
SABR. 
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Purpose or Objective: We aimed to establish the model 
predicting radiation-induced pulmonary function change after 
postoperative radiotherapy (PORT) in non-small cell lung 
cancer (NSCLC). 
 
Material and Methods: From March 2003 to December 2011, 
37 patients with NSCLC who underwent PORT were analyzed. 
All patients took the forced expiratory volume in 1 second 
(FEV1) at the beginning of PORT and follow-up FEV1 within 6-
36 months after the completion of PORT. We calculated 
mean lung dose (MLD) as a dosimetric parameter of the lung. 
Simple linear correlation and regression model were 
implemented to establish the prediction model between MLD 
and radiation-induced pulmonary function change. 
 
Results: The median absolute value of FEV1 at the beginning 
of PORT, and follow-up FEV1 were 1.76 L (range, 0.90-
3.05),and 1.66 L (range, 0.93-3.08), respectively. Radiation-
induced pulmonary function change (follow-up FEV1 minus 
FEV1 at beginning of PORT) ranged from -0.71 to 0.40 L 
(median, 0.06). The median MLD of PORT was 12.3 Gy (range, 
0.5-20.4). Radiation-induced FEV1 change and MLD showed 
statistically significant correlation (correlation coefficient = -
0.357, p = 0.030). PORT-induced FEV1 change could be 
predicted by simple linear regression model [FEV1 change (L) 
= 0.295 – 0.026 MLD (Gy)]. 
 
Conclusion: Radiation-induced FEV1 change was significantly 
correlated with MLD in patients with NSCLC who underwent 
surgery followed by PORT. Follow-up FEV1 after the 
completion of PORT can be predicted by simple linear 
regression model using this correlation. 
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Purpose or Objective: The benefits of addition of whole 
brain radiotherapy (WBRT) to stereotactic radiotherapy (SRT) 
with respect to overall survival of patients with brain 
metastases from non-small cell lung cancer (NSCLC) are 
unclear. Most of the published studies addressing this issue 
recruited the patients with diverse histology and primary 
sites, with only few focusing on NSCLC. We addressed this 
issue by evaluating institutional experience in efficacy of SRT 
plus WBRT vs. SRT alone or WBRT alone in patients with 
NSCLC. 
 
Material and Methods: The analysis encompassed 143 
patients with brain metastases from NSCLC, including 65 with 
squamous-cell cancer (45.5%), 53 adenocarcinoma (37.1%), 25 
NOS (17.4%). SRT alone was used in 52 patients (36.4%), 
WBRT alone in 33 patients (23.1%) and WBRT plus SRT in 58 
patients (40.5%). Two chief subgroups were considered: those 
with 1-3 brain metastases (121 patients, 84.6%) and those 
with >3 metastases (22 patients, 15.4%). WBRT doses ranged 
from 20-30 Gy in 3.0-4.0 Gy per fraction, SBRT was given in 
1-6 fractions (median 1 fraction) of 6-22 Gy (median 15 Gy).  
 
Results: 1-year actuarial overall survival was 8%, 6% and 27% 
for SRT, WBRT and SRT+WBRT respectively. The difference in 
overall survival among 143 patients treated with SRS+WBRT 
vs. SRS or WBRT was highly significant (p<0.0001). The 
difference in overall survival between SRS+WBRT vs. SRS or 
WBRT was also apparent in a subgroup of patients with 1-3 
metastases (1-year OS of 9%, 0% and 26%, respectively). By 
contrast, the differences in OS according to treatment were 
not significant among the patients with >3 metastases. A 
multivariate analysis showed that out of several variables 
considered only WBRT alone or SRT alone (HR=1.85, p=0.001) 
and age over 70 years (HR=2.08, p=0.005) were associated 
with unfavorable survival. 
 
Conclusion: Although conclusions from this study are limited 
by nonrandomized selection of the treatment schedule and 
some heterogeneity in prescription practice the data 
presented suggest that combination of WBRT and SRT vs. 
WBRT alone or SRT alone result in considerably improved 
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survival among the patients with 1-3 brain metastases from 
non-small cell lung cancer. 
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Purpose or Objective: To know the failure patterns and 
survival of T4N0-1 non-small cell lung cancer (NSCLC) treated 
with definitive radiotherapy. 
 
Material and Methods: Ninety five patients with T4N0-1 
NSCLC who received definitive radiotherapy with or without 
chemotherapy from May 2003 to Oct 2014 were 
retrospectively reviewed. Standard radiotherapy scheme was 
66 Gy in 30 fractions. Main concurrent chemotherapy regimen 
was weekly Paclitaxel 50 mg/m2 combined with Cisplatin 20 
mg/m2 or Carboplatin AUC 2. Primary outcome was overall 
survival (OS). Secondary outcomes were failure patterns and 
toxicities. 
 
Results: The median age was 64 (range, 34-90). Eighty eight 
percent (n=84) of patients had ECOG performance status 0-1 
and 42% (n=40) experienced pretreatment weight loss. Sixty 
percent (n=57) of patients had no metastatic regional lymph 
nodes. The median radiation dose was EQD2 67.1 Gy (range, 
56.9-83.3). Seventy one patients (75%) were treated with 
concurrent chemotherapy. Among them, 13 patients were 
also administered neoadjuvant chemotherapy. At the median 
follow-up of 21 months (range, 1-102), 3-year OS was 44%. 
Three-year cumulative incidence of local recurrence and 
distant recurrence were 48.8% and 36.3%. Pretreatment 
weight loss and combination of chemotherapy were 
significant factors in OS. Acute esophagitis over grade 3 was 
occurred in 3 patients and only one grade 3 chronic 
esophagitis was reported. There was no grade 3-4 radiation 
pneumonitis. 
 
Conclusion: Definitive radiotherapy for T4N0-1 NSCLC 
resulted in favorable survival with acceptable toxicity rates 
and local recurrence was a major pattern of recurrence. For 
improving local tumor control, the application of intensity 
modulated radiotherapy and radio-sensitizing agents would 
be needed. 
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Purpose or Objective: Stereotactic Body Radiation Therapy 
has become one of the standard treatments in Stage I NSCLC. 
However, there exists the problem of reoxygenation for large 
tumors and BED for serial organs locating near the central 
lung. Therefore, we have been treating especially these 
cases by decreasing the fraction dose while increasing overall 
treatment time and total dose (so-called hypofractionated 3-
dimensional noncoplanar conformal radiation therapy). To 
clarify the prognostic factors of this treatment method, we 
carried out this investigation. 
 
Material and Methods: Eligibility criteria were as follows: 
maximum tumor diameter not greater than 5cm, PS between 
0 and 2, and no limitation regarding age and pulmonary 
function. Radiotherapy was given with 6MV photon beam by 
fixed 10 non-coplanar conformal beams to a total dose of 
75Gy in 25 fractions in 5 weeks. Irradiation was aiming at the 
ITV with proper margins. No ENI was given. Between Jan. 
2002 and Jan. 2011, 109 eligible cases were treated. Age 
ranged from 53 to 93 (median 78). The male/female ratio 
was 79/30. There were 100 PS 1 and 9 PS 2 cases. There were 
22 low risk operable cases, 31 high risk operable cases 
(surgeons recommended RT), and 56 inoperable cases. There 
were 63 T1 tumors and 46 T2. Forty-six cases were central 
tumors and the other 63 were peripheral tumors. Seventy 
tumors were adenocarcinoma, 23 tumors were squamous cell 
carcinoma, and 16 others. Regarding tumor markers, 
pretreatment CEA was elevated (>5ng/ml) in 36 cases. Using 
these 8 parameters, multivariate analysis (MVA) for overall 
survival (OS) and local control (LC) was performed by Cox’s 
Proportional Hazard Model. Median follow-up period was 67 
months. 
 
Results: Five-year LC and OS rates were 84% and 50%, 
respectively. As for LC, MVA revealed that histology 
(p=0.0279) was prognostic and PS (p=0.0541) and 
pretreatment CEA (p=0.0560) had a tendency. As for OS, MVA 
revealed that gender (p=0.0081) and pretreatment CEA 
(p=0.0189) were prognostic and operability (p=0.0520) and 
histology (p=0.0913) had a tendency. On the other hand, age, 
T-stage or tumor location was not prognostic regarding 
neither LC nor OS. 
 
Conclusion: Our overall results of this method were 
promising considering the status of the patients. Regarding 
LC, adenocarcinomas were better controlled compared with 
other histologies, and patients with good PS and tumors with 
normal pretreatment CEA tended to be better controlled. 
Regarding OS, female patients, patients with normal 
pretreatment CEA survived better than their counterpart, 
and operable cases and adenocarcinoma cases tended to 
survive better than their counterpart, respectively. Unlike 
other reported series, T2 stage and central tumors did not 
carry worse prognoses with this treatment method. 
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Purpose or Objective: Stereotactic ablative radiotherapy 
(SABR) is an internationally accepted standard of care in the 
management of early stage medically inoperable NSCLC [1]. 
However, the issue of whether the excellent results of SABR 
for lung cancer can also be achieved when patients are 
treated outside pioneering academic institutions remains a 
pertinent one [2] 
South Tees NHS Trust is a large general hospital with a non-
academic cancer centre, serving a population of 1.1 million 
in the North-East of England. In 2009, we became the first 
non-academic cancer centre in the UK to establish a SABR 
programme. To date, over 200 patients have been treated 
with SABR. 
We present outcome data of 167 patients with Stage IA-IIB 
lung cancer, all of whom have at least 6 months of follow up 
and CT assessment of response. 
 
Material and Methods: Data was collected prospectively 
between Sept 2009 – Sept 2015. Only patients with stage IA-
IIB histologically proven NSCLC or PET +ve growing lesions, 
and at least 6 months of follow up, were included in the 
analysis. All patients were treated according to local 
protocols based on the national guidelines of the UK SABR 
Consortium.The following risk adapted treatment schedules 
were used depending on size and location of the tumour: 
54Gy in 3 fractions (40patients), 55Gy in 5 fractions (105pts), 
60Gy in 8 fractions (15pts), or 50Gy in 10 fractions (7pts) 
